Leukotriene D4-induced hypoxaemia in asthma is mediated by the cys-leukotrine1 receptor

European Respiratory Journal

Volumn 26, Issue 3, 2005, Pages 442-448

  Casas, A ^a   Gomez F P ^a   Dahlen B ^b   Roca, J ^a   Barbera J A ^a   Dahlen S E ^b   Rodriguez Roisin R ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Leukotriene inhalation challenge; Leukotriene receptor antagonists; Ventillation perfusion mismatching

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; INERT GAS; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR; MONTELUKAST; PEPTIDOLEUKOTRIENE; PLACEBO; SALBUTAMOL; ACETIC ACID DERIVATIVE; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEMBRANE PROTEIN; QUINOLINE DERIVATIVE;

ADULT; AIRWAY OBSTRUCTION; ARTERIAL OXYGEN TENSION; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPOXEMIA; LUNG DEAD SPACE; LUNG GAS EXCHANGE; LUNG VENTILATION PERFUSION RATIO; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HOSPITALIZATION; INHALATION TEST; PATHOPHYSIOLOGY;

ACETATES; ADULT; ANOXEMIA; ASTHMA; BRONCHIAL PROVOCATION TESTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; MALE; MEMBRANE PROTEINS; QUINOLINES; RECEPTORS, LEUKOTRIENE; SEVERITY OF ILLNESS INDEX; VENTILATION-PERFUSION RATIO;

EID: 24644464164     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00147504     Document Type: Article

References (32)

1. Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-1863.
2. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 323: 1736-1739.
3. Dahlen B, Roquet A, Inman MD, et al. Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. J Allergy Clin Immunol 2002; 109: 789-793.
4. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197-206.
5. Dockhorn RJ, Baumgartner RA, Leff JA, et al. Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax 2000; 55: 260-265.
6. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167: 528-533.
7. Rodriguez-Roisin R. Acute severe asthma: pathophysiology and pathobiology of gas exchange abnormalities. Eur Respir J 1997; 10: 1359-1371.
8. Echazarreta AL, Dahlen B, Garcia G, et al. Pulmonary gas exchange and sputum cellular responses to inhaled leukotriene D(4) in asthma. Am J Respir Crit Care Med 2001; 164: 202-206.
9. Brink C, Dahlen SE, Drazen J, et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 2003; 55: 195-227.
10. Ortiz JL, Gorenne I, Cortijo J, et al. Leukotriene receptors on human pulmonary vascular endothelium. Br J Pharmacol 1995; 115: 1382-1386.
11. Back M, Norel X, Walch L, et al. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol 2000; 401: 389-395.
12. Walch L, Norel X, Back M, Gascard JP, Dahlen SE, Brink C. Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br J Pharmacol 2002; 137: 1339-1345.
13. Global Initiative for Asthma (GINA). Global Strategy for asthma management and prevention. NHLBI/WHO Workshop Report. Publication No 02-3659 (updated 2002) Management Segment (Chapter 7): Updated 2004 from the 2003 document. The GINA reports are available on www.ginasthma.org.
14. De Lepeleire I, Reiss TF, Rochette F, et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997; 61: 83-92.
15. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 30531-30536.
16. Kumlin M, Dahlen B, Bjorck T, Zetterstrom O, Granstrom E, Dahlen SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 1992; 146:96-103.
17. Oostveen E, MacLeod D, Lorino H, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003; 22: 1026-1041.
18. Roca J, Wagner PD. Contribution of multiple inert gas elimination technique to pulmonary medicine. 1. Principles and information content of the multiple inert gas elimination technique. Thorax 1994; 49: 815-824.
19. Cardus J, Burgos F, Diaz O, et al. Increase in pulmonary ventilation-perfusion inequality with age in healthy individuals. Am J Respir Crit Care Med 1997; 156: 648-653.
20. Gale GE, Torre-Bueno JR, Moon RE, Saltzman HA, Wagner PD. Ventilation-perfusion inequality in normal humans during exercise at sea level and simulated altitude. J Appl Physiol 1985; 58: 978-988.
21. Drazen JM. Leukotrienes as mediators of airway obstruction. Am J Respir Crit Care Med 1998; 158: S193-S200.
22. Omini C, Folco GC, Vigano T, Rossoni G, Brunelli G, Berti F. Leukotriene-C4 induces generation of PGI2 and TXA2 in guinea-pig in vivo. Pharmacol Res Commun 1981; 13: 633-640.
23. Piper PJ, Samhoun MN. Stimulation of arachidonic acid metabolism and generation of thromboxane A2 by leukotrienes B4, C4 and D4 in guinea-pig lung in vitro. Br J Pharmacol 1982; 77: 267-275.
24. Dahlen SE, Hedqvist P, Westlund P, et al. Mechanisms of leukotriene-induced contractions of guinea pig airways: leukotriene C4 has a potent direct action whereas leukotriene B4 acts indirectly. Acta Physiol Scand 1983; 118: 393-403.
25. Echazarreta AL, Gomez FP, Ribas J, et al. Pulmonary gas exchange responses to histamine and methacholine challenges in mild asthma. Eur Respir J 2001; 17: 609-614.
26. Ballester E, Roca J, Rodriguez-Roisin R, Agusti-Vidal A. Effect of nifedipine on arterial hypoxaemia occurring after methacholine challenge in asthma. Thorax 1986; 41: 468-472.
27. Kumlin M. Measurement of leukotrienes in humans. Am J Respir Crit Care Med 2000; 161: S102-S106.
28. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149: 953-959.
29. Vachier I, Kumlin M, Dahlen SE, Bousquet J, Godard P, Chanez P. High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma. Respir Med 2003; 97: 1225-1229.
30. O'Shaughnessy KM, Wellings R, Gillies B, Fuller RW. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993; 147: 1472-1476.
31. Gomez FP, Iglesia R, Roca J, Barbera JA, Chung KF, Rodriguez-Roisin R. The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma. Am J Respir Crit Care Med 1998; 157: 1559-1564.
32. Casas A, Gomez FP, Rabinovich R, et al. Zafirlukast inhibits platelet activacting factor (PAF)-induced systemic, cellular and lung function abnormalities in asthma. Am J Respir Crit Care Med 2003; 168: A187.